Press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) and thromboembolic events
EventHumanCOVID-19Vaccines
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
Date
- Wednesday, 7 April 2021, All day
Location
- OnlineEuropean Medicines Agency, Amsterdam, the Netherlands
Event summary
EMA is holding a virtual press briefing on the conclusion of the evaluation of a safety signal with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) relating to cases of thromboembolic events by EMA’s safety committee (PRAC) on 7 April 2021.
Speakers:
- Emer Cooke (Executive Director)
- Sabine Straus (Chair of PRAC)
- Peter Arlett (Head of Data Analytics and Methods Task Force)
The press briefing will be moderated by Ms Marie-Agnes Heine (Head of Communication). The press briefing will be held in English.
Live broadcast - 16:00 - 16:45 CEST
|
To view the broadcast please ensure you meet the YouTube requirements. To view the video in the highest quality, click on the 'Settings' symbol in the right-hand corner of the video player and select '720p' or a higher resolution. |